SCHEMBL2348622

SCHEMBL2348622

Cc1ccc(C(=O)Nc2ccc(N3CCOCC3)cc2)cc1-c1ccc(C(=O)NCc2cccc(Cl)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.54
MAPK13 O15264 1/20 0.51
HSPB1 P04792 1/20 0.51
MAPK12 P53778 1/20 0.51
MAPK11 Q15759 1/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TP53 P04637 1/20 0.51
PKM P14618 1/20 0.51
MAPK1 P28482 1/20 0.51
RAF1 P04049 3/20 0.50
BRAF P15056 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
ROCK1 Q13464 1/20 0.50
LMNA P02545 1/20 0.48
ATM Q13315 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347316 0.96 MAPK14 (0.54) MAPK14MAPK13HSPB1MAPK12MAPK11
SCHEMBL2353573 0.92 MAPK14 (0.54) MAPK14NPC1RAB9ATP53PKM
SCHEMBL2347606 0.92 MAPK14 (0.55) MAPK14MAPK13HSPB1MAPK12MAPK11
SCHEMBL2344412 0.91 MAPK14 (0.57) MAPK14MAPK13HSPB1MAPK12MAPK11
SCHEMBL2349970 0.90 MAPK14 (0.54) MAPK14MAPK13HSPB1MAPK12MAPK11
SCHEMBL2350602 0.90 NAMPT (0.55) MAPK14MAPK13HSPB1MAPK12MAPK11
SCHEMBL2349181 0.90 MAPK14 (0.63) MAPK14MAPK13HSPB1MAPK12MAPK11
SCHEMBL2350840 0.89 KCNQ2 (0.60) MAPK14NPC1RAB9ARAF1BRAF
SCHEMBL2350529 0.88 RAF1 (0.61) RAF1BRAF
SCHEMBL2347109 0.88 RAB9A (0.53) MAPK14NPC1RAB9ATP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008303-B2 e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin ASTRAZENECA AB (SE) 2011-08-30 US disclosed
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 MAPK14 4315/4885MAPK13 4089/4885HSPB1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.